@article{article, title = {{Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial}}, publisher = {{Elsevier BV}}, url = {{}}, year = {{2022}}, month = {{4}}, author = {{Nanchahal J and Ball C and Rombach I and Williams L and Kenealy N and Dakin H and O'Connor H and Davidson D and Werker P and Dutton SJ and Feldmann M et al}}, doi = {{10.1016/s2665-9913(22)00093-5}}, volume = {{4}}, journal = {{The Lancet Rheumatology}}, issue = {{6}}, pages = {{E407-E416}}, note = {{Accessed on 2025/07/07}}}